AMAG Pharmaceuticals — FY2012 Earnings Presentation
12 slides from AMAG Pharmaceuticals's earnings presentation, Mar 15, 2013
Slide 1: AMAG Pharmaceuticals 2012 Financial Results
AMAG PHARMACEUTICALS 2012 Financial Results
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to: (i) o
Slide 3: AMAG: 2012 Highlights
AMAG: 2012 HIGHLIGHTS Continued growth of Feraheme U.S. CKD business Drove 17% Feraheme volume growth in the US compared to 2011 Exited year with 14% market share in grams Improved net revenue per gram for Feraheme Significant progress in Feraheme expansion efforts Completed phase III program for br
Slide 4: Feraheme US CKD Business
FERAHEME US CKD BUSINESS
Slide 5: 2012 – Strong Growth in Feraheme Provider Demand
2012 – STRONG GROWTH IN FERAHEME PROVIDER DEMAND 5 Source: IMS Health Data. 17% Grams 2012 Results 17% increase in Feraheme provider demand; 115 evolution index 4th Quarter Share 14% of non-dialysis IV iron market 26% of heme/onc segment 9% of hospital segment 37% of nephrology segment
Slide 6: Strong Feraheme Growth in Heme/Onc Segment
STRONG FERAHEME GROWTH IN HEME/ONC SEGMENT 6 Source: IMS Health Data. 63% 19% 12-Month Performance Feraheme up 19% Market up 6% 4Q12 vs. 4Q11 Feraheme up 11% Market up 2% Segment evolution index 109
Slide 7: Strong Feraheme Growth in Hospital Segment
STRONG FERAHEME GROWTH IN HOSPITAL SEGMENT 7 Source: IMS Health Data. 47% 33% 12-Month Performance Feraheme up 33% Market up 1% 4Q12 vs. 4Q11 Feraheme up 26% Market up 1% Segment evolution index 125
Slide 8: Feraheme Performing Well, With a Bright Future
FERAHEME PERFORMING WELL, WITH A BRIGHT FUTURE Continue to outpace market growth Gain access to untapped target heme/onc accounts Gain more hospital accounts Expand the IV iron market Present key data and medical meetings Continue to build awareness of Feraheme and of iron deficiency anemia 8
Slide 9: Financial Overview
| FINANCIAL OVERVIEW
Slide 10: Year-End Financial Highlights
YEAR-END FINANCIAL HIGHLIGHTS Balance Sheet $227 million in cash and investments as of December 31, 2012 ($ in millions, except per share ) 2012 2011 Change Total Revenues $85.4 $61.3 39% Net Feraheme US Product Revenues $58.3 $52.1 12% Cost of Product Sales $14.2 $10.5 35% R&D Expenses $33.3 $58.1
Slide 11: 2013 Financial Outlook
2013 FINANCIAL OUTLOOK 11 Expenses ($ in millions) Total Revenues of $73 - $77 million $63 – $67 million in Feraheme net U.S. product revenue Operating expenses of $78– $82 million (excluding COGS) R&D expenses decline New Investments for IDA launch COGS: 14%-18% of product sales End 2013 with $206
Slide 12: AMAG Pharmaceuticals: Well positioned for growth in 2013 and beyond
AMAG PHARMACEUTICALS Well positioned for growth in 2013 and beyond